Ranitidine (United States: Withdrawn from market): Drug information

For additional information see "Ranitidine (United States: Withdrawn from market): Patient drug information" and "Ranitidine (United States: Withdrawn from market): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: Canada

AG-Ranitidine [DSC];
APO-Ranitidine [DSC];
JAMP-Ranitidine [DSC];
M-Ranitidine [DSC];
MAR-Ranitidine;
MED Ranitidine;
MINT-Ranitidine;
PMS-Ranitidine [DSC];
RAN-Ranitidine [DSC];
Zantac C

Pharmacologic Category

Histamine H₂ Antagonist

Dosing: Adult

Aspiration prophylaxis in patients undergoing anesthesia

Aspiration prophylaxis in patients undergoing anesthesia: Oral: 150 mg the evening prior to anesthesia induction (recommended) or 150 mg two hours prior to anesthesia induction. May administer 150 mg every 6 hours in prepartum patients. May be given with a rapid-acting nonparticulate antacid (eg, sodium citrate).

Gastroesophageal reflux disease

Gastroesophageal reflux disease: Oral: Acute treatment: 150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks; in patients with moderate to severe esophagitis, may increase to 150 mg four times daily for up to 12 weeks; long-term maintenance: 150 mg twice daily.

NSAID-induced lesions

NSAID-induced lesions: Note: Although a labeled indication, H₂-receptor antagonists (eg, ranitidine) are not preferred for the treatment or prevention of NSAID-induced lesions due to the availability of proton pump inhibitors (PPIs) (Ref).

Oral: Treatment: 150 mg twice daily for 8 to 12 weeks; prevention: 150 mg twice daily administered concomitantly with NSAID.

Pathological hypersecretory conditions

Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome [gastrinoma]): Note: Although a labeled indication, clinical experience suggests that H₂-receptor antagonists (eg, ranitidine) are not preferred for controlling acid hypersecretion in pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) due to the availability of PPIs (Ref).

Oral: Initial: 150 mg three times daily; more frequent administration may be needed in some patients. Adjust dose to individual needs; doses up to 6 g/day have been tolerated.

Peptic ulcer disease

Peptic ulcer disease (duodenal or benign gastric ulcers) (alternative agent): Note: Although a labeled indication, current guidelines recommend PPIs as standard of care for treatment of peptic ulcer disease rather than H₂-receptor antagonists (eg, ranitidine) (Ref).

Initial: Oral: 300 mg once daily at bedtime or 150 mg twice daily for up to 8 weeks; may consider 300 mg twice daily for 4 weeks for more rapid healing.

Maintenance therapy: Oral: 150 mg once daily at bedtime; 300 mg once daily may be required in patients who smoke.

Stress ulcer prophylaxis in critically ill patients

Stress ulcer prophylaxis in critically ill patients:

Note: Some experts prefer a proton pump inhibitor rather than H₂-antagonists (eg, ranitidine)(Ref).

Oral: 150 mg twice daily; discontinue prophylaxis once risk factors have resolved (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl ≥50 mL/minute: No dosage adjustment necessary.

CrCl <50 mL/minute: Decrease dose by 50%; 150 mg every 24 hours is recommended.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Older Adult

Start at lowest recommended dose and adjust as needed; refer to adult dosing.

Dosing: Pediatric

(For additional information see "Ranitidine (United States: Withdrawn from market): Pediatric drug information")

Note : As of April 2020, all prescription (including oral and injectable) and OTC ranitidine formulations have been withdrawn from the US market.

Duodenal or gastric ulcer

Duodenal or gastric ulcer:

Treatment:

Infants, Children, and Adolescents ≤16 years:

Oral: 4 to 8 mg/kg/day divided twice daily; maximum daily dose: 300 mg/day.

IV: 2 to 4 mg/kg/day divided every 6 to 8 hours; maximum dose: 50 mg/dose.

Adolescents >16 years:

Oral:

Duodenal ulcer: 150 mg twice daily or 300 mg once daily after the evening meal or at bedtime.

Gastric ulcer: 150 mg twice daily.

IV, IM: 50 mg every 6 to 8 hours.

Maintenance:

Infants, Children, and Adolescents ≤16 years: Oral: 2 to 4 mg/kg/day once daily; maximum daily dose: 150 mg/day.

Adolescents >16 years: Oral: 150 mg once daily at bedtime.

Erosive esophagitis

Erosive esophagitis:

Infants, Children, and Adolescents ≤16 years: Oral: 5 to 10 mg/kg/day divided twice daily; maximum dose: 150 mg/dose.

Adolescents >16 years: Oral:

Treatment: 150 mg 4 times daily.

Maintenance: 150 mg twice daily.

GI bleed or stress ulcer; prophylaxis

GI bleed or stress ulcer; prophylaxis: Limited data available; dosing regimens variable:

Intermittent IV infusion:

Infants: 2 to 6 mg/kg/day divided every 8 hours (Ref).

Children and Adolescents: 2 to 6 mg/kg/day divided every 6 hours; maximum daily dose: 300 mg/day (Ref).

Continuous IV infusion: Infants, Children, and Adolescents: Initial: 0.15 to 0.5 mg/kg/dose for 1 dose, followed by infusion of 0.08 to 0.2 mg/kg/hour (2 to 5 mg/kg/day) (Ref).

Gastroesophageal reflux disease

Gastroesophageal reflux disease: Note: Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (Ref).

Infants, Children, and Adolescents: Oral: 5 to 10 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 300 mg/day (Ref).

Heartburn

Heartburn: OTC labeling: Note: Do not use for more than 14 days.

Prevention: Children ≥12 years and Adolescents: Oral: 75 to 150 mg 30 to 60 minutes before eating food or drinking beverages which cause heartburn; maximum daily dose: 2 doses/day.

Relief of symptoms: Children ≥12 years and Adolescents: Oral: 75 to 150 mg twice daily; maximum daily dose: 2 doses/day.

Pathological hypersecretory conditions

Pathological hypersecretory conditions (eg, Zollinger-Ellison): Note: Proton pump inhibitors are the preferred agents (Ref).

Adolescents >16 years:

Oral: 150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 g/day have been used.

Continuous IV infusion: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if >10 mEq/hour or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used.

Anaphylaxis, adjunctive therapy

Anaphylaxis, adjunctive therapy: Note: Should not be used as monotherapy or as first-line therapy (Ref).

Infants, Children, and Adolescents: IV: 1 mg/kg/dose; maximum dose: 50 mg/dose (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents (Ref):

Oral: Based on a usual dose of 2 to 6 mg/kg/day divided every 8 to 12 hours.

GFR >50 mL/minute/1.73 m²: No adjustment required.

GFR 30 to 50 mL/minute/1.73 m²: 2 mg/kg/dose every 12 hours.

GFR 10 to 29 mL/minute/1.73 m²: 1 mg/kg/dose every 12 hours.

GFR <10 mL/minute/1.73 m²: 1 mg/kg/dose every 24 hours.

Hemodialysis: 1 mg/kg/dose every 24 hours.

Peritoneal dialysis: 1 mg/kg/dose every 24 hours.

Continuous renal replacement therapy: 2 mg/kg/dose every 12 hours.

Parenteral (IV): Based on a usual dose of 2 to 4 mg/kg/day divided every 6 to 24 hours.

GFR >50 mL/minute/1.73 m²: No adjustment required.

GFR 30 to 50 mL/minute/1.73 m²: 1 mg/kg/dose every 12 hours.

GFR 10 to 29 mL/minute/1.73 m²: 0.5 mg/kg/dose every 12 hours.

GFR <10 mL/minute/1.73 m²: 0.5 mg/kg/dose every 24 hours.

Hemodialysis: 0.5 mg/kg/dose every 24 hours.

Peritoneal dialysis: 0.5 mg/kg/dose every 24 hours.

Continuous renal replacement therapy: 1 mg/kg/dose every 12 hours.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Atrioventricular block, bradycardia, premature ventricular contractions, tachycardia, vasculitis

Dermatologic: Alopecia, erythema multiforme, skin rash

Gastrointestinal: Abdominal distress, abdominal pain, constipation, diarrhea, nausea, necrotizing enterocolitis (very low birth weight neonates; Guillet 2006), pancreatitis, vomiting

Genitourinary: Breast changes (including galactorrhea not associated with childbirth, gynecomastia), erectile dysfunction

Hematologic & oncologic: Agranulocytosis, aplastic anemia, bone marrow depression, leukopenia, pancytopenia, thrombocytopenia

Hepatic: Cholestatic hepatitis, hepatitis, hepatocellular hepatitis, jaundice

Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)

Nervous system: Agitation, confusion, depression, dizziness, drowsiness, hallucination, headache (may be severe), insomnia, involuntary motor activity, malaise, vertigo

Neuromuscular & skeletal: Arthralgia, myalgia

Ophthalmic: Blurred vision

Renal: Acute interstitial nephritis, increased serum creatinine

Contraindications

Hypersensitivity to ranitidine or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Community-acquired pneumonia: An increased risk in developing community-acquired pneumonia has been reported in patients with chronic lung disease, diabetes, and/or immunocompromised and older patients when using H₂-receptor antagonists.

• Confusion: Rare cases of reversible confusion have been associated with ranitidine; usually elderly or severely ill patients, or in patients with renal or hepatic impairment.

• Vitamin B₁₂ deficiency: Prolonged treatment (≥2 years) may lead to vitamin B₁₂ malabsorption and subsequent vitamin B₁₂ deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (<30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).

Disease-related concerns:

• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.

• Porphyria: Avoid use in patients with a history of acute porphyria; may precipitate attacks.

Special populations:

• Children: Use of gastric acid inhibitors, including proton pump inhibitors and H₂ blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).

Warnings: Additional Pediatric Considerations

Use of gastric acid inhibitors, including proton pump inhibitors and H₂ blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients 4 to 36 months (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H₂ receptor antagonists; however, a causal relationship with ranitidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H₂ blocker use and an increased incidence of necrotizing enterocolitis (NEC) in very low birth weight (VLBW) neonates (Guillet 2006). An approximate six-fold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, urinary tract infection) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates (Terrin 2012). Routine use in preterm infants is not recommended (AAP [Eichenwald 2018]). Gastric acid suppression medications, including H₂ blockers, have also been associated with an increase in Clostridioides difficile infection (CDI) and recurrent CDI in pediatric patients (Nylund 2014).

Product Availability

Not available in the US.

Generic Equivalent Available: US

Pricing: US

Capsules (raNITIdine HCl Oral)

150 mg (per each): $1.52

300 mg (per each): $2.74

Solution (raNITIdine HCl Injection)

50 mg/2 mL (per mL): $7.73

150 mg/6 mL (per mL): $7.74

1000 mg/40 mL (per mL): $7.16

Solution (Zantac Injection)

50 mg/2 mL (per mL): $9.90

Syrup (raNITIdine HCl Oral)

15 mg/mL (per mL): $0.74

Tablets (raNITIdine HCl Oral)

75 mg (per each): $0.07

150 mg (per each): $1.48 - $1.75

300 mg (per each): $2.69 - $3.22

Tablets (Zantac 150 Maximum Strength Oral)

150 mg (per each): $0.34

Tablets (Zantac 75 Oral)

75 mg (per each): $0.30

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Zantac C: 150 mg, 300 mg [contains soybean lecithin]

Solution, Oral:

Generic: 15 mg/mL ([DSC])

Tablet, Oral:

Generic: 150 mg, 300 mg

Administration: Adult

Oral: Administer with or without food.

Administration: Pediatric

Oral: Administer with meals and/or at bedtime.

Parenteral:

IV: Must be diluted prior to administration; may be administered IV push, intermittent IV infusion, or continuous IV infusion.

Intermittent IV infusion: Preferred over IV push to decrease risk of bradycardia; infuse over 15 to 20 minutes.

IV push: Manufacturer recommends administering over a period of at least 5 minutes, not to exceed 10 mg/minute (4 mL/minute).

Continuous IV infusion: Administer at ordered rate; titration may be necessary for some conditions.

IM: Administer undiluted.

Usual Infusion Concentrations: Pediatric

IV infusion: 0.5 mg/mL

Use: Labeled Indications

Note: Not approved in the United States.

Aspiration prophylaxis in patients undergoing anesthesia: Prevention of acid aspiration syndrome from general anesthesia in at-risk patients (eg, obstetrical patients in labor, patients with obesity).

Gastroesophageal reflux disease: Treatment of reflux esophagitis.

NSAID-induced lesions: Treatment of NSAID-induced lesions (eg, ulcers, erosions) and associated GI symptoms; prevention of NSAID-induced lesion recurrence.

Note: Although a labeled indication, H₂-receptor antagonists (eg, ranitidine) are not preferred for the treatment or prevention of NSAID-induced lesions due to the availability of proton pump inhibitors (PPIs) (Ref).

Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome [gastrinoma]): Treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Note: Although a labeled indication, clinical experience suggests that H₂-receptor antagonists (eg, ranitidine) are not preferred for controlling acid hypersecretion in pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) due to the availability of PPIs (Ref).

Peptic ulcer disease: Treatment of duodenal, benign gastric, or postoperative peptic ulcers; prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration prophylaxis of recurrent hemorrhage from bleeding ulcers.

Note: Although a labeled indication, current guidelines recommend PPIs as standard of care for treatment of peptic ulcer disease rather than H₂-receptor antagonists (eg, ranitidine) (Ref).

Stress ulcer prophylaxis in critically ill patients: Prophylaxis of GI hemorrhage from stress ulceration in critically ill patients (Ref).

Medication Safety Issues

Sound-alike/look-alike issues:

RaNITIdine may be confused with amantadine, riMANTAdine

Metabolism/Transport Effects

Substrate of CYP1A2 (Minor), CYP2C19 (Minor), CYP2D6 (Minor), OCT1, OCT2, P-glycoprotein (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acalabrutinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Acalabrutinib. Management: Give acalabrutinib capsules 2 hours before a histamine H2 receptor antagonist (H2RA). No action is required if acalabrutinib tablets are coadministered with H2RAs. Risk D: Consider Therapy Modification

Atazanavir: Histamine H2 Receptor Antagonists may decrease serum concentration of Atazanavir. Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information. Risk D: Consider Therapy Modification

Belumosudil: Histamine H2 Receptor Antagonists may decrease serum concentration of Belumosudil. Risk C: Monitor

Bosutinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Bosutinib. Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib. Risk D: Consider Therapy Modification

Cefditoren: Histamine H2 Receptor Antagonists may decrease serum concentration of Cefditoren. Risk X: Avoid

Cefpodoxime: Histamine H2 Receptor Antagonists may decrease serum concentration of Cefpodoxime. Risk C: Monitor

Cefuroxime: Histamine H2 Receptor Antagonists may decrease absorption of Cefuroxime. Management: Avoid concomitant use of oral cefuroxime axetil and H2 receptor antagonists if possible. If combined, ensure oral cefuroxime axetil is taken with food to minimize the magnitude of this interaction. Risk D: Consider Therapy Modification

Cysteamine (Systemic): Histamine H2 Receptor Antagonists may decrease therapeutic effects of Cysteamine (Systemic). Risk C: Monitor

Dacomitinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Dacomitinib. Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA). Risk D: Consider Therapy Modification

Dasatinib: Histamine H2 Receptor Antagonists may decrease absorption of Dasatinib. Management: Do not administer H2RAs with dasatinib. Antacids (taken 2 hours before or after dasatinib) can be used in place of H2-antagonists if some acid-reducing therapy is needed. No interaction is expected with the Phyrago brand of dasatinib. Risk X: Avoid

Doxofylline: RaNITIdine may increase serum concentration of Doxofylline. Risk C: Monitor

Erlotinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Erlotinib. Management: Avoid H2-antagonists in patients receiving erlotinib when possible. If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing. Risk D: Consider Therapy Modification

Fosamprenavir: Histamine H2 Receptor Antagonists may decrease serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. Risk C: Monitor

Gefitinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Gefitinib. Management: Administer gefitinib at least 6 hours before or 6 hours after administration of a histamine H2 receptor antagonist (H2RA), and closely monitor clinical response to gefitinib. Risk D: Consider Therapy Modification

GlipiZIDE: RaNITIdine may increase serum concentration of GlipiZIDE. Risk C: Monitor

GlyBURIDE: RaNITIdine may increase hypoglycemic effects of GlyBURIDE. Risk C: Monitor

Indinavir: Histamine H2 Receptor Antagonists may decrease serum concentration of Indinavir. Risk C: Monitor

Itraconazole: Histamine H2 Receptor Antagonists may increase serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease serum concentration of Itraconazole. Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by H2RAs; consider itraconazole dose reduction. Risk D: Consider Therapy Modification

Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease serum concentration of Ketoconazole (Systemic). Management: Administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor for reduced efficacy if concomitant use with a H2RA is required. Increases in ketoconazole dose may be required. Risk D: Consider Therapy Modification

Ledipasvir: Histamine H2 Receptor Antagonists may decrease serum concentration of Ledipasvir. Management: Administer H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily simultaneously or 12 hours prior to ledipasvir. The effect of administering H2 receptor antagonists at other time intervals is unknown and not recommended. Risk D: Consider Therapy Modification

Levoketoconazole: Histamine H2 Receptor Antagonists may decrease absorption of Levoketoconazole. Risk X: Avoid

Lomitapide: RaNITIdine may increase serum concentration of Lomitapide. Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent ranitidine; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose). Risk D: Consider Therapy Modification

Lumacaftor and Ivacaftor: May decrease serum concentration of RaNITIdine. Lumacaftor and Ivacaftor may increase serum concentration of RaNITIdine. Risk C: Monitor

Nelfinavir: Histamine H2 Receptor Antagonists may decrease serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. Histamine H2 Receptor Antagonists may decrease active metabolite exposure of Nelfinavir. Risk C: Monitor

Neratinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction. Risk D: Consider Therapy Modification

NIFEdipine (Topical): RaNITIdine may increase serum concentration of NIFEdipine (Topical). Risk C: Monitor

Nilotinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Nilotinib. Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction. Risk D: Consider Therapy Modification

Nirogacestat: Histamine H2 Receptor Antagonists may decrease serum concentration of Nirogacestat. Risk X: Avoid

Octreotide: Histamine H2 Receptor Antagonists may decrease serum concentration of Octreotide. Risk C: Monitor

PAZOPanib: Histamine H2 Receptor Antagonists may decrease serum concentration of PAZOPanib. Risk X: Avoid

Pexidartinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Pexidartinib. Management: Administer pexidartinib 2 hours before or 10 hours after histamine H2 receptor antagonists. Risk D: Consider Therapy Modification

Posaconazole: Histamine H2 Receptor Antagonists may decrease serum concentration of Posaconazole. Risk C: Monitor

Procainamide: RaNITIdine may increase serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite. Risk C: Monitor

Rilpivirine: Histamine H2 Receptor Antagonists may decrease serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists (H2RAs) at least 12 hours before or 4 hours after oral rilpivirine. Risk D: Consider Therapy Modification

Risedronate: Histamine H2 Receptor Antagonists may increase serum concentration of Risedronate. This applies specifically to delayed-release risedronate. Risk X: Avoid

Saquinavir: Histamine H2 Receptor Antagonists may increase serum concentration of Saquinavir. Management: Consider alternatives to this combination for patients taking the Invirase formulation of saquinavir. No action beyond standard clinical care measures is required for patients taking the Fortovase formulation of saquinavir. Risk D: Consider Therapy Modification

Secretin: Coadministration of Histamine H2 Receptor Antagonists and Secretin may alter diagnostic results. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration. Risk D: Consider Therapy Modification

Selpercatinib: Histamine H2 Receptor Antagonists may decrease serum concentration of Selpercatinib. Management: Coadministration of selpercatinib and H2 receptor antagonists should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 10 hours after H2 receptor antagonists. Risk D: Consider Therapy Modification

Sotorasib: Histamine H2 Receptor Antagonists may decrease serum concentration of Sotorasib. Risk X: Avoid

Sparsentan: Histamine H2 Receptor Antagonists may decrease serum concentration of Sparsentan. Risk X: Avoid

Sulpiride: Histamine H2 Receptor Antagonists may decrease serum concentration of Sulpiride. Management: Consider alternatives to this combination, such as antacids given 2 hours after sulpiride, if possible. This does not apply when sulpiride and H2RAs are intentionally coadministered for the treatment of duodenal ulcers. Risk D: Consider Therapy Modification

Triazolam: RaNITIdine may increase serum concentration of Triazolam. Risk C: Monitor

Velpatasvir: Histamine H2 Receptor Antagonists may decrease serum concentration of Velpatasvir. Risk C: Monitor

Warfarin: RaNITIdine may increase serum concentration of Warfarin. Risk C: Monitor

Food Interactions

Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B₁₂ and subsequent vitamin B₁₂ deficiency (Lam 2013).

Pregnancy Considerations

Ranitidine crosses the placenta (Armentano 1989).

Breastfeeding Considerations

Ranitidine is present in breast milk.

Monitoring Parameters

AST, ALT, serum creatinine; occult blood with GI bleeding, signs/symptoms of peptic ulcer disease; when used to prevent stress-related GI bleeding, measure the intragastric pH and try to maintain pH >4; when used for Zollinger-Ellison syndrome, monitor gastric acid secretion (goal: <10 mEq/hour); signs of confusion

Mechanism of Action

Competitive inhibition of histamine at H₂-receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: 50%.

Distribution: V_d: 96 to 142 L.

Protein binding: ~15%.

Metabolism: Hepatic (minor) to N-oxide, S-oxide, and N-desmethyl metabolites.

Half-life elimination: 2 to 3 hours.

Time to peak, serum: 2 to 3 hours.

Excretion: Urine (as unchanged drug): 35%; feces: 26%; bile: <3%.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Plasma levels are increased and elimination is prolonged in patients with altered kidney function.

Hepatic function impairment (compensated cirrhosis): Studies found minor but clinically significant differences in half-life, bioavailability, clearance, and volume of distribution.

Pediatric: In pediatric cardiac failure, clearance may be reduced. In a prospective population pharmacokinetic study of critically ill pediatric patients (n=78; age range: 15 days to 15.51 years), cardiac failure/surgery was found to reduce clearance by a factor of 0.463 (Hawwa 2013).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Antagonin | Apo ranitidine | Glotac | Histac | Nadine | Novo-ranidine | Pylorid | Ranacid | Ranid | Ranidine | Ranimax | Ranimed | Ranitcare | Rantag | Ranzin | Zantac;
(AR) Argentina: Acidex | Alivian | Dualid | Espaven | Espaven Extra Forte | Faboacid r | Fada ranitidina | Fendibina | Gastrial | Gastrosedol | Gastrozac | Labsidex | Notrab | Pylorid | Ranitic | Ranitidina celtyc | Ranitidina denver farma | Ranitidina ilab | Ranitidina lazar | Ranitidina millet | Ranitidina Pharma | Ranitidina Rigo | Ranitidina unc | Ranitidina vent 3 | Ranitral | Ranitul | Raticina | Reco | Sustac | Taural | Teogrand | Ulcotenk | Vingional | Zantac;
(AT) Austria: Pylorisin | Ranic | Raninorm | Ranitidin 1a pharma gmbh | Ranitidin Accord | Ranitidin arcana | Ranitidin genericon pharma | Ranitidin Ranbaxy | Ranitidin ratiopharm | Ranitidin Sandoz | Ranitidin stada arzneihmittel gmbh | Ranityrol | Ulsal | Zantac;
(AU) Australia: Acid & heart burn | Amcal heartburn relief | Apo ranitidine | Apohealth ranitidine acid & heartburn relief | Ausran | Biochemie heartburn relief | Cm acid&heartburn | Cm ranitidine | CO Ranitidine | Dbl ranitidine | Gastrogel ranitidine | Gavilast | Gavilast 12 hour action | Heartburn relief | Medix | Mylanta | Mylanta 12 hour | Pharmacy action heartburn & acid indigestion relief | Pharmacy care heartburn relief | Pharmacy health reflux relief | Rani | Ranihexal | Ranital | Ranitidine | Ranitidine an | Ranitidine gh | Ranitidine sandoz | Ranitidine-bc | Ranoxyl | Sbpa ranitidine | Tw acid&h/burn rlf | Tw ranitidine | Ulcaid | Ultac | Zantac | Zantac relief;
(BD) Bangladesh: Aceptin R | Acin | Alin | Amuran | Anitid | Antac | Antamin-R | Bentid | Bitack | Centac | Ceptin r | Denitid | Denitine | Detac | Dimeran | Dugal | Duran | Editin-r | Ethidin | Exac | G-ranitidin | H blok | Hi-Tac | Inran | Inseac | Lucin-r | Lumeran | Mystin-r | Neoceptin r | Neodin | Neodin-s | Neofast-s | Neopep | Neosetin R | Neotack | Neotid | Neotidin | Neotin | Norma-H | Normacid | Off h | Ortac | Peotide | Peptidin | Peptil h | Peptosol | Protec-r | Q-ran | Radin | Ranbex | Rani | Ranicare | Ranid | Ranidin | Raniloc | Ranisis | Ranison | Ranit | Ranitab | Ranitack | Ranitec | Ranitid | Ranitidine | Ranitidine-r | Ranitor | Ranix | Rantec | Rantin | Ranul | Recodin | Redin | Reetac-R | Renicon | Rhine | Rn | Rostid | Rotid | Rt | Sutac | Tinadin | Tytac | Ulcar | Ultac | Unitac | Veridin | Wintack | Xantid | Xantid hs | Xardin | Z-ranid | Zactin | Zantac | Zenil | Zodin | Zorep | Zostac;
(BE) Belgium: Docraniti | Pylorid | Ranitidine bexal | Ranitidine eurogenerics | Ranitidine merck-generics | Ranitidine Ratiopharm | Ranitidine sandoz | Ranitidine teva | Zantac;
(BF) Burkina Faso: Rani denk;
(BG) Bulgaria: Histac | Raniberl | Ranitidin | Razidin | Zantac;
(BR) Brazil: Antagon | Antak | Antidin | Aziliv | Bloculcer | Cloridrato de ranitidina | Ethenem | Gastak | Genotak | Iquego ranitidina | Label | Lfm ranitidina | Logat | Neosac | Nititom | Pylorid | Ramifabra | Raniclor | Ranidin | Ranidina | Ranidine | Ranidolim | Raniflex | Ranilup | Ranimax | Ranitak | Ranitidil | Ranitidina | Ranitil | Ranitinol | Ranition | Ranitrat | Ranitzen | Ranytisan | Regalil | Rhanitak | Tazepin | Tekadin | Ulcerit | Ulcerocin | Ulcoren | Zadine | Zylium;
(CH) Switzerland: Ranimed | Ranisifar | Ranitidin cophar | Ranitidin-mepha | Zantic;
(CI) Côte d'Ivoire: Acidac | Rani denk | Ranimat | Zynol;
(CL) Chile: Ranicel | Ranitax | Ranitidina | Uldine | Zantac;
(CN) China: Dong yi | Ge lai shi | Histac | Jin de le | Lan bai xing | Ou hua da | Pylorid | Qi di | Ranitidine | Ranitidine hydrochloride and sodium chloride | Ranitidine hydrochloride in sodium chloride | Rui bei | Shan de kang | Shang wei | Xi si da | Xi si ta | Yi li shu | Zantac;
(CO) Colombia: Azanplus | Clorimed | Gastrelin | Peptiran | Ragastro | Raldin | Rancet | Raniclorh | Ranidin | Ranidox | Ranimed | Raniogas | Ranipep | Raniphar | Ranisul | Raniter | Ranitidina | Ranitidina mk | Ranitil | Regastin | Reycid | Ul-pep | Ulcuran | Uldin | Ulpigas | Ultidin | Zantac;
(CZ) Czech Republic: Apo ranitidine | Eradipak | Histac | Ranisan | Ranital | Ranitidine aurovitas | Ulran | Zantac;
(DE) Germany: Azantac | Azuranit | Junizac | Milinda rani-nerton | Phamoranit | Ran lich | Rani | Rani biochemie | Rani nerton | Rani sanorania | Raniberl | Ranibeta | Ranibloc | Ranicux | Ranidura | Ranidura t | Raniprotect | Ranitab | Ranitic | Ranitidin | Ranitidin 1a pharma | Ranitidin atid | Ranitidin AWD | Ranitidin axsan | Ranitidin basics | Ranitidin Heumann | Ranitidin Heumann Heunet | Ranitidin ratiopharm | Ranitidin Siga | Ranitidin stada | Ranitidin-Isis | Ranitidin-saar | Ranitidoc | Raniwieb | Sostril | Zantic;
(DK) Denmark: Acikure | Ranicodan | Ranitidin ratiopharm;
(DO) Dominican Republic: Apoprin | Durak | Fendibina | Pylorid | Ran H2 | Randil | Ranifur | Ranilap | Raniogas | Ranisen | Ranitidina | Ranitidina cinfa | Ranitidina normon | Taural | Tiroran | Ulciflax | Ulgasin | Ulsana | Zantac;
(EC) Ecuador: It Ranichem | Libradina | Nitidan | Pylorid | Radinat | Ranicid | Raniogas | Ranitab | Ranitidina | Ranitidina genfar | Ranitidina mk | Ranitidina R | Stomacid | Taural | Tiroran | Zantac;
(EE) Estonia: Acidex | Kuracid | Pylorid | Raniberl | Ranideks | Ranigast | Ranisan | Ranitidin | Ranitidin alpharma | Ranitidin ratiopharm | Ranitidine accord | Zantac;
(EG) Egypt: Aciloc | Epiran | Gastproct | Gastroprotect | Histac | Osmoran | Pylorid | Ranicap | Ranitak | Ranitidine | Ranitidol | Rantag | Rantiblock | Rantidine | Rantidol | Zantac;
(ES) Spain: Arcid | Ardoral | Coralen | Denulcer | Quantor | Ran H2 | Ranidin | Ranitidina aurovitas | Ranitidina bexal | Ranitidina Edigen | Ranitidina grapa | Ranitidina grifols | Ranitidina lareq | Ranitidina mabo | Ranitidina merck | Ranitidina mundogen | Ranitidina normon | Ranitidina Pensa | Ranitidina pharmagenus | Ranitidina Ratiopharm | Ranitidina tarbis | Ranitidina Teva | Ranitidina vir | Ranix | Ranuber | Rubiulcer | Tanidina | Terposen | Toriol | Underacid | Zantac;
(ET) Ethiopia: Rani denk | Ranitidine | Ranitol | Rantag | Zantac;
(FI) Finland: Esofex | Pylorid | Ranicur | Ranicur gerard | Ranil | Ranimex | Ranisan | Ranitidin alpharma | Ranitidin merck nm | Ranitidin pliva | Ranitidin stada | Ranitidine ranbaxy | Ranitidine sandoz | Ranixal | Zantac;
(FR) France: Azantac | Raniplex | Ranitidine | Ranitidine accord | Ranitidine Biogaran | Ranitidine g gam | Ranitidine gnr | Ranitidine ivax | Ranitidine merck | Ranitidine Ratiopharm | Ranitidine RPG | Ranitidine sandoz | Ranitidine teva;
(GB) United Kingdom: Dumoran | Galpharm ranitidine | Gavilast | Gavilast-p | Heartbur antacid | Histac | Peach Ethical | Pylorid | Raciran | Ranicalm | Ranitic | Ranitidine | Ranitidine almus | Ranitidine arrow | Ranitidine cox | Ranitidine kent | Ranitidine sandoz | Ranitil | Rantec | Ranzac | Vivatak | Zaedoc | Zantac | Zantac 75;
(GR) Greece: Alphadine | Aova | Baroxal | Blumol | Brixoral | Ceftrinal | Ezopta | Galebiron | Gaproxen | Lomadryl | Lumaren | Narigen | Odanet | Ptinolin | Pylorid | Raniclon | Ranitidine | Ranitidine/Generics | Ranitidine/mylan | Semuele | Smaril | Specinor | Synthomanet | Tupast | Zantac | Zoliden | Zurfix;
(HK) Hong Kong: Apo ranitidine | Eurotac | Glotac | Hyzan | Kanacid | Karitidine | Kin pak | Lumeran | Neo tac | Pylorid | Quicran | Radin | Ranatec | Randac | Ranicone | Ranidine | Ranital | Ranitid | Ranitidina cinfa | Ranitidine | Ranolta | Rantacid | Rantin | Simetac | Ulticer | Uni-Rantac | Vesyca | Weicotac | Weidos | Zantac | Zanticaine | Zantidon | Zendhin;
(HR) Croatia: Bloculcer | Peptoran | Peptoran MAX | Ranital | Ranitidin Europharma | Ranitidin lek | Ranitidin Sandoz | Ranix | Rantin;
(HU) Hungary: Histac | Huma-ranidine | Pylorid | Ranitic | Ranitidin 1 A Pharma | Ranitidin-b | Ulceran | Ulcosin | Umaren | Zantac;
(ID) Indonesia: Aciblock | Acran | Aldin | Bloxer | Chopintac forte | Conranin | Curadyn | Fordin | Gastridin | Graseric | Harmidin | Hexer | Indoran | Omeramine | Radin | Ranal | Rancus | Ranilex | Ranin | Ranitab | Ranitidin | Ranitidine | Ranivel | Ranoxin | Rantag | Ranticid | Rantin | Ratinal | Renatac | Scanarin | Titan | Tricker-150 | Tyran | Ulceranin | Uldinal | Wiacid | Xeradin | Zantac | Zantadin | Zantifar | Zenti | Zumaran;
(IE) Ireland: Gertac | Pylorid | Ranitic | Ranitidine | Ranopine | Xanomel | Zandine | Zantac;
(IL) Israel: Apozan | Zanidex | Zantab | Zantac;
(IN) India: Aciloc | Aciran | Acirid | Agiloc | Alprodine | Alurin | Antac | Aztec | Dentac | Din | Emeltidine | Emtac | Gertac | Giran | H2loc | Healcer | Healthy rani | Helkoss | Histac | Intac | Kamtac | Kaytec | Lantac | Lydin | Monorin | Natidine | Nicotac | Niratin | Nit | Peploc | R-loc | Rafilon | Rancafe | Rancer | Randinat | Ranial | Ranibid | Ranicer | Ranicom | Ranicool | Ranilink | Ranimax | Ranin | Ranipep | Ranisun | Ranit | Ranitas | Raniter | Ranitidine | Ranitidine HCL | Ranitin | Ranizac | Ranizen | Ranloc | Ranpep | Rantac | Rantica | Ranwell | Rd | Rdin | Relitin | Renact | Renicret | Renitab | Ridcer | Rintin | Rintric | S.tac | Saintac | Skytac | Tidac | Tydin | Ulceran | Ulfast | Ultac | Ultidin | Z-ran | Zinetac | Zoran | Zynol | Zytak;
(IT) Italy: Dolilux | Elicodil | Pylorid | Raniben | Ranibloc | Ranidil | Ranitidina | Ranitidina Angenerico | Ranitidina D&G | Ranitidina doc | Ranitidina DRM | Ranitidina eg | Ranitidina Hexal | Ranitidina Ibirn | Ranitidina jet | Ranitidina Magis | Ranitidina Merck Generics | Ranitidina new | Ranitidina Pantafarm | Ranitidina Ranbaxy | Ranitidina sandoz | Sensigard | Ulcex | Zantac;
(JO) Jordan: Antagonin | Nadine | Peptac | Pylorisin | Ranacid | Ranid | Ranidine | Zantac;
(JP) Japan: Braulibera | Hatsker | Lanizac | Lantic | Raden | Raitadin | Ranimerck | Ranitac | Ranitidine | Ranitizane | Ranitizane amel | Seochitozin | Tsurudek | Zamec | Zantac;
(KE) Kenya: Aciloc | Neotack | R loc | Rancer | Rani denk | Ranison | Ranitidine agio | Ranitin | Rantac | Rantag | Reducid | Renitab | Rinatadin | Ultac | Zantac | Zerocid;
(KR) Korea, Republic of: Alsanon | Anitin | Aprogen ranitidine | Austin ranitidine hcl | Barogrin | Bc ranitidine | Bitidine | Camillan | Camilran | Celtidin | Cudin | Curan | Curitin | Curodine | Dactel | Duractin | Eltidine | Exta f | Gadin | Garantine | Gastidine | Gi-easy | Gl ranitidine | Hunitin | Huran | Hutecs ranitidine | I ran | I ranitidine | Ilyangbio ranitidine | Inotidine | Jan q pro | Jeidin | Jeil maxtidin plus | Jenitin | Jera q | Jinradine | Katiring | Keibitidine | Kms ranitidine | Kwangdong ranitidine | Kyongbo ranitidine | Locid | Luratin | Marutin | Medira | Megatin | Nelson ranitidine | Neotidine | Panstac | Pharmgen ranitidine | Ponaltin | Pylorid | Qutidin | Racidine | Radin q | Radine | Raditine | Radubadine | Ranacid | Randin | Rani s | Ranibic | Ranibig | Ranicos | Ranid | Ranidan | Ranidin | Ranidine | Ranidon | Ranidone | Ranidro | Ranikim | Raniking | Ranil | Ranis | Ranisca | Ranisen | Ranitac | Raniten | Ranitid | Ranitidine | Ranitidine hyosung | Ranitiem | Ranitigen | Ranitina | Ranition | Ranitiran gold | Ranitop | Ranix | Ranizan | Rantin | Rantine | Rantis | Raqunin | Raticon | Ratigen | Ratinnis | Ratudin | Renitine | Restidine | Ribotin | Rp ranitidine hcl | Rtd | Samnam ranitidine | SCD Ranitidine | Scheinedin | Tarana | Tinatin | Tinoq | Tritin | U-rantac | Ulcemed | Unidin | Urantac | Winatac | Wiradin | Wizan | Wontac | Wooritin | Xansiq | Xantas f | Youngpoong ranitidine | Yuhan ranitidine hcl | Zan q 75 | Zanci q | Zancid L | Zandark | Zani q | Zanpro | Zansta | Zanstin | Zantac | Zantini | Zatidine | Zellatidine | Zenitin | Zenix | Zyniq;
(KW) Kuwait: Apo ranitidine | Glotac | Navidine | Pylorid | Ranacid | Ranid | Ranitcare | Rantag | Rantin | Zantac;
(LB) Lebanon: Antagonin | Glotac | Nadine | Ptinolin | Pylorid | Ranacid | Ranicux | Ranimat | Raniplex | Ranitidine | Rantag | Ulticer | Zantac;
(LT) Lithuania: Acidex | Aciloc e | Apo ranitidine | Histac | Pylorid | Raniberl | Raniday | Ranigast | Ranisan | Ranitab | Ranital | Ranitidin | Ranitidin al | Ranitidin bp | Ranitidina normon | Ranitidine accord | Ranitidine siromed | Rantac | Ulcosan | Ulran | Zantac | Zoran;
(LU) Luxembourg: Docraniti | Pylorid | Ranitic | Ranitidine eg | Ranitidine mylan | Zantac;
(LV) Latvia: Acidex | Aciloc | Histac | Raniberl | Ranidex | Ranigast | Ranitab | Ranital | Ranitidin | Ranitidina | Ranitidine accord | Ranitidinum | Ranitin | Rantac | Ultak | Zantac | Zoran;
(MA) Morocco: Acidac | Azantac | Pylorid | Ranimat | Ranitil | Tanidine | Xanidine;
(MX) Mexico: Acloral | Acloral b.i. | Agrisen | Alter h2 | Apodatina | Azanplus | Azantac | Azantac f | Deratin | Dinaxin | Driges | Ducan | Durak | Flatmed | Galidrin | Gastridin | Genotidina | Iqfadina | Katalem | Microtid | Radyn | Ranifur | Raniger | Ranisen | Ranitab | Ranitidina | Ranitidina avivia | Ranitidina gi | Ranitidina gi leme | Ranitidina gi phar | Ranitidina gi serr | Ranitidina Kendrick | Ranitidina Wermar | Ranitinida | Raudil | Redacid | Serranit | Sinhcloran | Solrasol | Syngasy | Terodul | Tianak | Tidibuffin | Ulmodhyl | Ulsaven | Unitin | Vistac;
(MY) Malaysia: Apo ranitidine | Gastril | Histac | Hyzan | Ranitic | Ranitidine | Rantac | Rintac | Vesyca | X'tac | Xanomel | Zantac | Zendhin;
(NG) Nigeria: Aciloc | Ranivan | Softhealth ranitidine | Timetidine | Topix ranitidine | Zaridex;
(NL) Netherlands: Azantac | Pylorid | Ranitidine | Ranitidine A | Ranitidine accord | Ranitidine cf | Ranitidine mdq | Ranitidine teva | Zantac;
(NO) Norway: Pylorid | Ranacid | Ranitidin | Ranitidin al | Ranitidin gea | Ranitidine | Ranitidine accord | Ranitidine rosemont | Ranitidine sandoz | Zantac | Zantac euromedica;
(NZ) New Zealand: Apo ranitidine | Arrow-ranitidine | Gavilast | Peptisoothe | Ranitidine relief | Zanidin | Zantac | Zantac relief;
(OM) Oman: Zantac;
(PE) Peru: Aciflux | Atural | Galtidin | Gastriflam | Histac | Ranifur | Ranimek | Ranit | Ranitax | Ranitidina | Ulceran | Ulcip | Zantac;
(PH) Philippines: Amloc | Boie ranitidine | Ceranid | Contracid | Cygran | Entac | Eu-ran | Gastrone | Incid | Intac | Mordek | Pep Bloc | Peptica | Pylorid | Radine | Ramadine | Ranae | Ranid | Ranitab | Ranitein | Ranix | Rapidin | Ratidin | Raxide | Renfort | Ritemed Ranitidine | Ulcemed | Ulceragon | Ulceral | Ulcergo | Ulcerix | Ulci bloc | Ulcin | Ulzim | Zantac | Zidaxim | Zilatec;
(PK) Pakistan: Adetac | Anzol | Certine | Dart | Degust | Dinetac | Duotec | Glamet | H2 rec | Hitac | Lomadryl | Melfax | Mifotec | Neotack | Nilcer | Nitid | Nulcer | Obatidine | Peptac | Pepticure | Peptinil | Purod | Rakitac | Ramedac | Ranacid | Ranax | Rancer | Ranidin | Ranidol | Raniloc | Ranimax | Ranimed | Ranin | Ranipep | Raniscot | Ranison | Ranizan | Rantid | Rantin | Ranulcid | Ratac | Reliance | Renacid | Renata | Renatil | Reneph | Renera | Ritadine | S cid | Stomacid | Tanidina | Ulcemed | Ulcenor | Ulcer Off | Ulcerid | Ulcetac | Ultec | Ulzan | Xancid | Xetac | Zantac | Zantidon | Zenit;
(PL) Poland: Apo ranitidine | Histac | Novo-ranidine | Raniberl | Raniberl max | Ranic | Ranigast | Ranigast max | Ranigast pro | Ranimax | Ranisan | Ranital | Ranitin | Ranitydyna | Ranitydyna aurovitas | Riflux | Zantac;
(PR) Puerto Rico: Acid reducer | Gabitidine | Ranitidine | Ranitidine HCL | Tritec | Zantac;
(PT) Portugal: Bloculcer | Gastridina | Gastrimuto | Gastrolav | Pep Rani | Peptab | Peptifar | Pylorid | Ran | Ranitidina | Stacer | Ulcecur | Zantac;
(PY) Paraguay: Ranitidina genfar | Ranitidina vent 3 | Teogrand;
(QA) Qatar: Acicare | Antagonin | Apo-Ranitidine | Glotac | Nadine | Navidine | Peptac | Qranid | Ragasit | Ranacid | Rani-nerton | Ranid | Ranidine | Ranimax AC | Ranitak | Ranitidine Mabo | Rantag | Rolan | Zantac | Zydac;
(RO) Romania: Digen | Ranitab | Ranital | Ranitidin | Ranitidin helcor | Ranitidin Ranbaxy | Ranitidina arena | Ranitidina atb | Ranitidina Laropharm | Ranitidina lph | Ranitidina slavia | Ranitin | Ulcoran | Zantac;
(RU) Russian Federation: Acidex | Aciloc e | Histac | Novo ranitidine | Pylorid | Raniberl | Ranigast | Ranisan | Ranison | Ranitab | Ranital | Ranitidin | Ranitidin akri | Ranitidin Olainfarm | Ranitidine | Ranitidine akos | Ranitidine ferein | Ranitidine lekt | Ranitin | Rantac | Rantak | Renx | Ulcodin | Zantac | Zantin | Zoran;
(SA) Saudi Arabia: Acicare | Antagonin | Apo ranitidine | Glotac | Nadine | Navidine | Novo-ranidine | Peptac | Pms ranitidine | Pylorid | Ranacid | Ranid | Ranidin | Ranidine | Ranimax | Ranimax ac | Rantag | Ranzin | Tanidina | Zydac;
(SE) Sweden: Artonil | Inside | Rani-q | Ranitidin actavis | Ranitidin alpharma | Ranitidin apofri | Ranitidin Hexal | Ranitidin medartuum | Ranitidin mylan | Ranitidin nm pharma | Ranitidin pliva | Ranitidin ratiopharm | Ranitidin recip | Ranitidin stada | Ranitidine ranbaxy | Zantac;
(SG) Singapore: Aciloc | Apo ranitidine | Histac | Hyzan | Neoceptin r | Pylorid | Radine | Rani denk | Ranidine | Ranitidina | Ranitidine | Sp-gastril | Vesyca | Xanadine | Zantac | Zendhin | Zynol;
(SI) Slovenia: Pylorid | Ranital | Ulran | Zantac;
(SK) Slovakia: Histac | Ranisan | Ranital | Zantac;
(SR) Suriname: Apo ranitidine | Azantac | Novo ranitidine | Rani denk | Ranitidine | Ranitidine accord | Ranloc | Zantac;
(TH) Thailand: Acicare | Aciloc | Apo ranitidine | Histac | Oltak | Pylorid | Radine | Ranicid | Ranid | Ranidine | Ranitidine | Rantac | Ranto | Rantodine | Ratic | Utac | Xanidine | Zanamet | Zantac | Zantidon;
(TN) Tunisia: Antagonine | Tanidina;
(TR) Turkey: Pylorid | Ranit | Ranobel | Rozon | Ulcuran | Zandid | Zantac;
(TW) Taiwan: Apo ranitidine | Curan | Getway | Kiradin | Kowecan | Nicewe | Novo-ranidine | Quicran | Ranidine | Ranitidine | Rannine | Rnd | Sontac | Ulsafe | Vesyca | Weichilin | Weidos | Wintac | Zantac;
(UA) Ukraine: Acidex | Aciloc e | Histac | Raniberl | Ranitidin | Ranitidine | Ranitidine euro | Ranitidine forte | Ranitin | Rantac | Rinit | Umetak | Zantac | Zoran;
(UG) Uganda: R loc | Rani denk;
(UY) Uruguay: Acigastrol | Acitran | Binacil | Binacil-s | Lunadina | Miniac | Nulacid | Ranitidina | Ranitidina lazar | Ranitidina Phs Pharmaservice | Sustac | Taural | Zantac;
(VE) Venezuela, Bolivarian Republic of: Aplom | Enteral | Gastac | Pylorid | Ranic | Ranitidina | Ranitidina G.C. | Ranix | Retamin | Ultidine | Vizerul | Zantac | Zoran;
(VN) Viet Nam: Kantacid;
(ZA) South Africa: Apex ranitidine | Apo ranitidine | Austac | Be-tabs ranitidine | Cpl alliance ranitidine | Garec-Ranitidine | Gi-tak | Gulf ranitidine | Histak | Ranihexal | Ranitidine | Ranitidine biotech | Ranteen | Simayla ranitidine | Ultak | Zantac;
(ZM) Zambia: Aciloc | R-loc | Rani denk | Ranitin | Ranloc | Rintid | Ultac;
(ZW) Zimbabwe: Ranitin | Zynol

2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM; NSAID-Associated Gastric Ulcer Study Group. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med. 2000;160(10):1455-1461. doi:10.1001/archinte.160.10.1455 [PubMed 10826458]
American Society of Anesthesiologists. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016;124(2):270-300. doi: 10.1097/ALN.0000000000000935. [PubMed 26580836]
American Society of Anesthesiologists. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology. 2017;126(3):376-393. doi: 10.1097/ALN.0000000000001452. [PubMed 28045707]
American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347-379. [PubMed 10690219]
Armentano G, Bracco PL, Di Silverio C. Ranitidine in the treatment of reflux oesophagitis in pregnancy. Clin Exp Obstet Gynecol. 1989;16(4):130-133. [PubMed 2627742]
Aronoff GR, Bennett WM, Berns JS, et al, eds. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019;171(11):805-822. doi:10.7326/M19-1795 [PubMed 31634917]
Birch JL, Newell SJ. Gastrooesophageal reflux disease in preterm infants: current management and diagnostic dilemmas. Arch Dis Child Fetal Neonatal Ed. 2009;94(5):F379-F383. doi:10.1136/adc.2008.149112 [PubMed 19307225]
Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014;113(6):599–608. doi:10.1016/j.anai.2014.10.007 [PubMed 25466802]
Canani RB, Cirillo P, Roggero P, et al; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817-e820. [PubMed 16651285]
Cheng A. Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health. 2011;16(1):35-40. [PubMed 22211074]
Coursin DB, Farin-Rusk C, Springman SR, et al, “The Hemodynamic Effects of Intravenous Cimetidine versus Ranitidine in Intensive Care Unit Patients: A Double-Blind, Prospective, Cross-Over Study,” Anesthesiology, 1988, 69(6):975-8. [PubMed 3057942]
Crill CM and Hak EB, "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients," Pharmacotherapy, 1999, 19(2):162-80. [PubMed 10030767]
Eichenwald EC; Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants [published online July 2, 2018]. Pediatrics. 2018. [PubMed 29915158]
Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.
Goelzer SL, Farin-Rusk C, and Coursin DB, “Ranitidine Produces Minimal Hemodynamic Depression in Stable Intensive Care Unit Patients: A Double-Blind, Prospective Study,” Crit Care Med, 1988, 16(1):8-10. [PubMed 3276451]
Guarnotta V, Martini C, Davì MV, et al. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine. 2018;60(1):15-27. doi:10.1007/s12020-017-1420-4 [PubMed 29019150]
Guillet R, Stoll BJ, Cotten CM, et al, "Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants," Pediatrics, 2006, 117(2):137-42. [PubMed 16390920]
Hawwa AF, Westwood PM, Collier PS, et al. Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. Br J Clin Pharmacol. 2013;75(5):1265-1276. [PubMed 23016949]
Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2013;14(3):307-321. doi:10.1517/14656566.2013.767332 [PubMed 23363383]
Kelly EJ, Chatfield SL, Brownlee KG, et al. The effect of intravenous ranitidine on the intragastric pH of preterm infants receiving dexamethasone. Arch Dis Child. 1993;69(1 Spec No):37-39. doi:10.1136/adc.69.1_spec_no.37 [PubMed 8346951]
Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
Kuusela AL. Long-term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates. Arch Dis Child Fetal Neonatal Ed. 1998;78(2):F151-F153. doi:10.1136/fn.78.2.f151 [PubMed 9577289]
Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245 [PubMed 33929377]
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-2422. [PubMed 24327038]
Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update [published correction appears in J Allergy Clin Immunol. 2010;126(6):1104]. J Allergy Clin Immunol. 2010;126(3):477-480. [PubMed 20692689]
Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019. [PubMed 26505932]
Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131(5):e1684-1695. [PubMed 23629618]
Lugo RA, Harrison AM, Cash J, Sweeley J, Vernon DD. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med. 2001;29(4):759-764. [PubMed 11373465]
MacLaren R, Dionne JC, Granholm A, et al. Executive summary-Society of Critical Care Medicine guideline and American Society of Health-System Pharmacists for the prevention of stress-related gastrointestinal bleeding in critically ill adults. Crit Care Med. 2024;52(8):1295-1299. doi:10.1097/CCM.0000000000006329 [PubMed 39007570]
MINT-Ranitidine tablets [product monograph]. Mississauga, Ontario, Canada: Mint Pharmaceuticals Inc; April 2022.
Nelson WE, Behrman RE, Kliegman RM, et al, eds. Nelson Textbook of Pediatrics. 15th ed. WB Saunders Company; 1996.
Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. J Pediatr. 2014;165(5):979-84.e1. [PubMed 25112692]
Osteyee JL, Banner W Jr. Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children. Am J Crit Care. 1994;3(4):267-272. [PubMed 7920954]
Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516-554. [PubMed 29470322]
Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2008;29(5):481-496. doi:10.1111/j.1365-2036.2008.03905.x [PubMed 19053986]
Simons FE, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7(1):9. [PubMed 24920969]
Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32. [PubMed 26525001]
Smith CL, Bardgett DM, and Hunter JM, “Haemodynamic Effects of the I.V. Administration of Cimetidine or Ranitidine in the Critically Ill Patient: A Double-Blind Prospective Study,” Br J Anaesth, 1987, 59(11):1397-1402. [PubMed 3689613]
Sutphen JL, Dillard VL. Effect of ranitidine on twenty-four-hour gastric acidity in infants. J Pediatr. 1989;114(3):472-474. doi:10.1016/s0022-3476(89)80576-1 [PubMed 2921693]
Terrin G, Passariello A, De Curtis M, et al, "Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns," Pediatrics, 2012, 129(1):40-5. [PubMed 22157140]
Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. World J Gastroenterol. 2005;11(35):5423-5432. doi:10.3748/wjg.v11.i35.5423 [PubMed 16222731]
Weinhouse GL. Stress ulcers in the intensive care unit: diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed May 4, 2022.
Wells TG, Heulitt MJ, Taylor BJ, Fasules JW, Kearns GL. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol. 1998;38(5):402-407. doi:10.1002/j.1552-4604.1998.tb04443.x [PubMed 9602950]
Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr. 2009;155(4):516-521. doi:10.1016/j.jpeds.2009.03.044 [PubMed 19540518]
Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med. 1998;338(11):719-726. doi:10.1056/NEJM199803123381104 [PubMed 9494148]
Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care. 2002;17(4):240-245. [PubMed 12501151]

Topic 9853 Version 595.0

خرید پکیج

Ranitidine (United States: Withdrawn from market): Drug information